본문 바로가기

Urgency to treat patients with chronic hepatitis C in Asia

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY32(5) · pp.966 · 2017
피인용
Web of Science 18Scopus 20
FWCI (Scopus)
0.72
JCR IF
JCR 2016 3.452
ISSN
0815-9319

저자

  1. Kao, Jia-Horng제1저자교신저자National Taiwan University College of Medicine, Taipei, Taiwan
  2. Ahn, Sang HoonYonsei University College of Medicine, Seoul, South Korea
  3. Chien, Rong-NanChang-Gung Memorial Hospital, Kee-Lung Branch, Keelung, Taiwan
  4. 조몽Pusan National University Yangsan Hospital, Busan, South Korea
  5. Chuang, Wan-LongKaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
  6. Jeong, Sook-HyangSeoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
  7. Liu, Chen-HuaNational Taiwan University Hospital, Taipei, Taiwan
  8. Paik, Seung-WoonSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

초록

Chronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South, and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for chronic hepatitis C vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians. However, low efficacy, poor safety profile, and subcutaneous administration limit the use of IFN-based therapies. Superior virologic outcomes have been observed with different classes of direct-acting antivirals (DAAs) alone or in combination, and several all-oral DAA regimens are available in Asia. These regimens have shown excellent efficacy and favorable tolerability in clinical trials, yet there is a need for further studies of DAAs in a real world context, particularly in Asia. Furthermore, IFN-free treatment may not be accessible for many patients in the region, and IFN-based regimens remain an option in some countries. There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost-effectiveness of IFN-free regimens. The evolution of potent treatments makes HCV eradication a possibility that should be available to all patients. However, access to these therapies in Asian countries has been slow, primarily because of economic barriers that continue to present a hurdle to optimal treatment.

키워드

AsiaclinicalHCV clinical trialsHCV treatmenthepatitis CDACLATASVIR PLUS ASUNAPREVIRSUSTAINED VIROLOGICAL RESPONSETREATMENT-EXPERIENCED PATIENTSGENOTYPE 1B INFECTIONVIRUS-INFECTIONJAPANESE PATIENTSOPEN-LABELPEGINTERFERON ALPHA-2ATREATMENT-NAIVEPHASE-3 TRIAL

식별자

Scopus EID
2-s2.0-85018691362
WoS UID
000400339400008